Harrow (HROW) Non-Current Assets (2010 - 2026)
Harrow (HROW) posted quarterly Non-Current Assets of $193.2 million for Q1 2026, down 0.76% year-over-year from $194.6 million in Q1 2025, and up 2.89% quarter-over-quarter from $187.7 million in Q4 2025.
Harrow (HROW) Non-Current Assets (2010 - 2026) Analysis & Trends
Harrow's Non-Current Assets history runs 16 years deep, the most recent figure standing at $193.2 million for Q1 2026.
- In Q1 2026, Non-Current Assets fell 0.76% year-over-year to $193.2 million; the TTM figure through Mar 2026 stood at $756.5 million (down 1.2% YoY), while the FY2025 annual figure was $187.7 million, down 5.81% from the prior year.
- Non-Current Assets for Q1 2026 stood at $193.2 million, up from $187.7 million in the prior quarter.
- The five-year high for Non-Current Assets was $204.5 million in Q3 2024, with the low at $107000.0 in Q4 2022.
- The 5-year median for Non-Current Assets is $170.1 million (2024), against an average of $110.0 million.
- The sharpest annual moves came in 2022 and 2023: Non-Current Assets tumbled 74.03% in 2022, then soared 161285.05% in 2023.
- Harrow's Non-Current Assets stood at $107000.0 in 2022, then jumped by 161285.05% to $172.7 million in 2023, then gained by 15.43% to $199.3 million in 2024, then declined by 5.81% to $187.7 million in 2025, then grew by 2.89% to $193.2 million in 2026.
- Business Quant data shows HROW's Non-Current Assets at $193.2 million in Q1 2026, $187.7 million in Q4 2025, and $185.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | 37.96 Bn |
| 2 | Teva Pharmaceutical Industries | 43.42 Bn | 39.76 Bn | 2.15 Bn | 26.10 Bn |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | 8.72 Bn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.98 Bn | 5.10 Bn | 78.51 Bn |
| 5 | United Therapeutics | 22.29 Bn | 19.63 Bn | 683.80 Mn | 3.74 Bn |
| 6 | Viatris | 18.78 Bn | 17.89 Bn | 1.46 Bn | 24.99 Bn |
| 7 | Neurocrine Biosciences | 15.66 Bn | 15.27 Bn | 935.80 Mn | 3.72 Bn |
| 8 | Elanco Animal Health | 11.91 Bn | 11.38 Bn | 798.00 Mn | 9.76 Bn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | 2.96 Bn |
| 10 | Harrow | 1.59 Bn | 1.51 Bn | 50.36 Mn | 187.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 187.51 Mn |
| Mar 31, 2026 | 193.16 Mn |
| Dec 31, 2025 | 187.73 Mn |
| Sep 30, 2025 | 185.47 Mn |
| Jun 30, 2025 | 190.14 Mn |
| Mar 31, 2025 | 194.63 Mn |
| Dec 31, 2024 | 199.32 Mn |
| Sep 30, 2024 | 204.48 Mn |
| Jun 30, 2024 | 167.24 Mn |
| Mar 31, 2024 | 170.08 Mn |
| Dec 31, 2023 | 172.68 Mn |
| Sep 30, 2023 | 780,000.00 |
| Jun 30, 2023 | 808,000.00 |
| Mar 31, 2023 | 902,000.00 |
| Dec 31, 2022 | 107,000.00 |
| Sep 30, 2022 | 994,000.00 |
| Jun 30, 2022 | 661,000.00 |
| Mar 31, 2022 | 411,000.00 |
| Dec 31, 2021 | 412,000.00 |
| Sep 30, 2021 | 36,000.00 |